Literature DB >> 22075221

Evaluation of hypophosphatemia: lessons from patients with genetic disorders.

Justine Bacchetta1, Isidro B Salusky.   

Abstract

Phosphate is a key component of several physiologic pathways, such as skeletal development, bone mineralization, membrane composition, nucleotide structure, maintenance of plasma pH, and cellular signaling. The kidneys have a key role in phosphate homeostasis, with 3 hormones having important roles in renal phosphate handling: parathyroid hormone, fibroblast growth factor 23 (FGF-23), and 1,25-dihydroxyvitamin D. Independent of the genetic diseases affecting the FGF-23 pathway (such as hypophosphatemic rickets), hypophosphatemia is a frequent condition encountered in daily practice, and untreated critical hypophosphatemia can induce hemolysis, rhabdomyolysis, respiratory failure, cardiac dysfunction, and neurologic impairment. Rapid correction thus is necessary to avoid severe complications. The aims of this teaching case are to summarize the causes and biological evaluation of hypophosphatemia and provide an overview of our current understanding of phosphate metabolism.
Copyright © 2011 National Kidney Foundation, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22075221      PMCID: PMC4324571          DOI: 10.1053/j.ajkd.2011.08.035

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  37 in total

Review 1.  Evaluation of bone and mineral disorders.

Authors:  Laleh Ardeshirpour; David E C Cole; Thomas O Carpenter
Journal:  Pediatr Endocrinol Rev       Date:  2007-10

Review 2.  Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit.

Authors:  N C Bugg; J A Jones
Journal:  Anaesthesia       Date:  1998-09       Impact factor: 6.955

Review 3.  Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

4.  Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.

Authors:  Sherri -Ann M Burnett; Samantha C Gunawardene; F Richard Bringhurst; Harald Jüppner; Hang Lee; Joel S Finkelstein
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

5.  Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Hejing Wang; Robert M Elashoff; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

6.  Dental abnormalities and oral health in patients with Hypophosphatemic rickets.

Authors:  Melissa Almeida Souza; Luiz Alberto Valente Soares Junior; Marcela Alves Dos Santos; Maria Helena Vaisbich
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

7.  Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism.

Authors:  Takehisa Kawata; Yasuo Imanishi; Keisuke Kobayashi; Takami Miki; Andrew Arnold; Masaaki Inaba; Yoshiki Nishizawa
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

8.  A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet.

Authors:  Helge Raeder; Nick Shaw; Coen Netelenbos; Robert Bjerknes
Journal:  Eur J Endocrinol       Date:  2008-09-05       Impact factor: 6.664

9.  Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.

Authors:  Uri S Alon; Rachel Levy-Olomucki; Wayne V Moore; Jason Stubbs; Shiguang Liu; L Darryl Quarles
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

10.  Metabolic and orthopedic management of X-linked vitamin D-resistant hypophosphatemic rickets.

Authors:  Sandro F Fucentese; Thomas J Neuhaus; Leonhard E Ramseier; G Ulrich Exner
Journal:  J Child Orthop       Date:  2008-07-26       Impact factor: 1.548

View more
  9 in total

1.  FGF23 in chronic kidney disease: are we lost in translation?

Authors:  Justine Bacchetta
Journal:  Bonekey Rep       Date:  2016-01-06

Review 2.  Can features of phosphate toxicity appear in normophosphatemia?

Authors:  Satoko Osuka; Mohammed S Razzaque
Journal:  J Bone Miner Metab       Date:  2012-01-05       Impact factor: 2.626

3.  Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?

Authors:  Debora Claramunt-Taberner; Aurélia Bertholet-Thomas; Marie-Christine Carlier; Frédérique Dijoud; Franck Chotel; Caroline Silve; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2018-03-28       Impact factor: 3.714

4.  Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.

Authors:  Justine Bacchetta; Jessica L Sea; Rene F Chun; Thomas S Lisse; Katherine Wesseling-Perry; Barbara Gales; John S Adams; Isidro B Salusky; Martin Hewison
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

Review 5.  Management of hyperphosphataemia in chronic kidney disease-challenges and solutions.

Authors:  Markus Ketteler; Rudolf P Wüthrich; Jürgen Floege
Journal:  Clin Kidney J       Date:  2013-01-16

6.  Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis.

Authors:  Per-Anton Westerberg; Torbjörn Linde; Dirk Vanderschueren; Jaak Billen; Ivo Jans; Östen Ljunggren
Journal:  Clin Kidney J       Date:  2012-03-29

7.  Phosphorus bioaccessibility measured in four amino acid-based  formulas using in-vitro batch digestion translates well into phosphorus bioavailability in mice.

Authors:  Sampada Chande; Francina Dijk; Jonathan Fetene; Steven Yannicelli; Thomas O Carpenter; Ardy van Helvoort; Clemens Bergwitz
Journal:  Nutrition       Date:  2021-04-28       Impact factor: 4.893

8.  More Bone with Less Minerals? The Effects of Dietary Phosphorus on the Post-Cranial Skeleton in Zebrafish.

Authors:  Silvia Cotti; Ann Huysseune; Wolfgang Koppe; Martin Rücklin; Federica Marone; Eva M Wölfel; Imke A K Fiedler; Björn Busse; Antonella Forlino; P Eckhard Witten
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

9.  An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia.

Authors:  Fahad Aljuraibah; Justine Bacchetta; Maria Luisa Brandi; Pablo Florenzano; Muhammad K Javaid; Outimaija Mäkitie; Adalbert Raimann; Mariano Rodriguez; Heide Siggelkow; Dov Tiosano; Marc Vervloet; Carsten A Wagner
Journal:  J Bone Miner Res       Date:  2021-12-23       Impact factor: 6.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.